It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.

As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Oxbryta, one of at least six treatments for the disease, is mostly used in patients with mild-to-moderate symptoms. The drug received accelerated approved in the U.S. in 2019, requiring further ...

Pfizer PFE-0.21%decrease; red down pointing triangle said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

(Reuters) - The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta. Pfizer said late ...

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to ...

Oxbryta, one of at least six treatments for the disease, is mostly used in patients with mild-to-moderate symptoms. The drug received accelerated approved in the U.S. in 2019, requiring further trials ...